The efficacy and safety of lomitapide as adjunct treatment for adults with homozygous familial hypercholesterolaemia (HoFH) have been confirmed in a phase 3 trial. Given the small number of patients (N = 29), and variations in patient characteristics, examining individual cases provides additional details regarding patient management with lomitapide. Here, we examine the details of the Italian patient cohort in the phase 3 trial.
Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort / Averna, M; Cefalù, A. B; Stefanutti, Claudia; Di Giacomo, S; Sirtori, C. R; Vigna, G.. - In: NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. - ISSN 0939-4753. - ELETTRONICO. - 26:1(2016), pp. 36-44-44. [10.1016/j.numecd.2015.11.001]
Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort
STEFANUTTI, Claudia;Di Giacomo, S;
2016
Abstract
The efficacy and safety of lomitapide as adjunct treatment for adults with homozygous familial hypercholesterolaemia (HoFH) have been confirmed in a phase 3 trial. Given the small number of patients (N = 29), and variations in patient characteristics, examining individual cases provides additional details regarding patient management with lomitapide. Here, we examine the details of the Italian patient cohort in the phase 3 trial.| File | Dimensione | Formato | |
|---|---|---|---|
|
Averna_Individual-analysis_2016.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.45 MB
Formato
Adobe PDF
|
1.45 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
